Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Recruiting 1Completed 1

Sponsor Class

NIH 1NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 7Sarcoma 6Lymphoid 5Myeloid 3CNS 2Gastrointestinal 1

Conditions

Ganglioneuroblastoma 2Neuroblastoma 1

Interventions

Temozolomide 165Magnetic Resonance Spectroscopy 130Radiotherapy 95Specimen Handling 80Radiosurgery 60Cyclophosphamide 55pembrolizumab 51Bevacizumab 51Nivolumab 48Radiation 47Carboplatin 34Biopsy 33Irinotecan 29Lomustine 25Etoposide 25Vincristine 23Topotecan 23Ipilimumab 23dinutuximab 21Cisplatin 21Blood Specimen Collection 21fludarabine 19Radiotherapy, Intensity-Modulated 19X-Rays 18Surgical Procedures, Operative 18abemaciclib 16Mental Status and Dementia Tests 16Granulocyte-Macrophage Colony-Stimulating Factor 16Pemetrexed 15atezolizumab 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Dexrazoxane × CNS × 1 year × Clear all
NCT03786783 2026-06-02

Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma

National Cancer Institute (NCI)

Phase 2 Completed
42 enrolled 12 charts
CNS

Ganglioneuroblastoma

NCT03126916 2026-02-27

Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)

Children's Oncology Group

Phase 3 Recruiting
750 enrolled
CNS

Neuroblastoma, Ganglioneuroblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡